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ABSTRACT
CEBPB copy number gain in Ewing sarcoma was previously shown to be associated 
with worse clinical outcome compared to tumors with normal CEBPB copy number, 
although the mechanism was not characterized. We employed gene knockdown 
and rescue assays to explore the consequences of altered CEBPB gene expression 
in Ewing sarcoma cell lines. Knockdown of EWS-FLI1 expression led to a decrease 
in expression of all three C/EBPβ isoforms while re-expression of EWS-FLI1 rescued 
C/EBPβ expression. Overexpression of C/EBPβ-1, the largest of the three C/EBPβ 
isoforms, led to a significant increase in colony formation when cells were grown in 
soft agar compared to empty vector transduced cells. In addition, depletion of C/EBPβ 
decreased colony formation, and re-expression of either C/EBPβ-1 or C/EBPβ-2 rescued 
the phenotype. We identified the cancer stem cell marker ALDH1A1 as a target of C/
EBPβ in Ewing sarcoma. Furthermore, increased expression of C/EBPβ led to resistance 
to chemotherapeutic agents. In summary, we have identified CEBPB as an oncogene 
in Ewing sarcoma. Overexpression of C/EBPβ-1 increases transformation, upregulates 
expression of the cancer stem cell marker ALDH1A1, and leads to chemoresistance.
INTRODUCTION
Ewing sarcoma is the second most common bone 
cancer in children and young adults. While the cell 
of origin is not known, histologically it is comprised 
of characteristic small round blue cells. This disease 
has a poor outcome, with a 60% survival rate for 
localized disease and less than 20% survival for 
metastatic disease [1, 2]. Ewing sarcoma is defined 
by a translocation of the EWSR1 gene to one of the 
ETS transcription factor family members, most 
commonly FLI1. This t(11;22) translocation encodes a 
fusion protein that acts as an oncogene by aberrantly 
transcribing genes involved in cellular proliferation 
and transformation [3, 4]. EWS-FLI1 binds with high 
affinity to GGAA microsatellite repeats within the 
promoter regions of its target genes [5, 6]. Investigation 
into the function of EWS-FLI1 target genes may help 
to identify disease risk factors and to develop novel 
treatments for Ewing sarcoma [7, 8].
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We previously performed high resolution SNP 
microarray analysis with Molecular Inversion Probe 
(MIP) technology on 40 FFPE primary tumors from 
patients diagnosed with Ewing sarcoma in Utah [9]. We 
identified both known and novel regions of recurring 
copy number alterations (CNAs) and correlated our 
findings with clinical features including outcome. In our 
Utah cohort, chromosome 20q showed trisomy in 15% 
(N = 6/40) of tumors. This included 3 samples that had 
whole chromosome 20 gain, while 3 had chromosome 
20q gain only. Of these three with chromosome 20q gain, 
one sample contained a very high gain (11 copies) within 
the 20q trisomy. This focal region in 20q13.13 was 575 
kilobase pairs in length and centered on CCAAT/enhancer 
binding protein beta (CEBPB). Immunohistochemical 
staining showed increased C/EBPβ nuclear staining in 
this and other Ewing sarcoma samples with CEBPB gain 
compared to other Ewing sarcoma tumors and non-tumor 
controls with normal CEBPB copy number. The Ewing 
sarcoma sample with the high-gain of 11 copies showed 
the most intense IHC nuclear staining indicating increased 
C/EBPβ protein expression. Additionally, CEBPB gains 
correlated with worse outcome (EFS P = 0.012, OS 
P = 0.00013) [9]. Recent genomic landscape of Ewing 
sarcoma publications support our observation of trisomy 
in chromosome 20q in approximately 15% of Ewing 
sarcoma tumors [10, 11], suggesting that a copy number 
gain in this region may confer a survival disadvantage for 
these patients. 
CEBPB encodes C/EBPβ, a leucine-zipper 
transcription factor involved in cellular metabolism, 
development, and differentiation [12–14]. Three protein 
isoforms of C/EBPβ (C/EBPβ-1, C/EBPβ-2, and C/EBPβ-
3) are expressed through the use of alternate translational 
start sites [15]. These isoforms have distinct biological 
functions depending on the cellular context [16–19]. 
C/EBPβ is important for mesenchymal cell differentiation 
(a possible cell of origin for Ewing sarcoma) and promotes 
osteoblast differentiation [20, 21]. C/EBPβ also plays a 
role in promoting cellular proliferation and transformation 
in other cancer types, including skin cancer, breast cancer, 
and anaplastic lymphoma [12, 22, 23]. In addition, 
C/EBPβ expression levels are increased in a number of 
different tumor types [24]. While the literature supports 
a role for C/EBPβ in cancer and bone development, a 
C/EBPβ-driven mechanism in Ewing sarcoma has not yet 
been described. Our data indicate that C/EBPβ plays an 
oncogenic role in Ewing sarcoma and is regulated by the 
Ewing sarcoma causative translocation, EWS-FLI1. 
C/EBPβ is a transcriptional regulator of aldehyde 
dehydrogenase 1A1 (ALDH1A1), a member of a family of 
detoxifying enzymes responsible for oxidizing aldehydes, 
in breast cancer cells [25]. ALDH is a proposed marker 
of cancer stem cells and ALDH activity has been used 
to identify cancer stem cells in breast, lung, and prostate 
cancer, among others [26–28]. Ewing sarcoma cells 
contain an ALDH-high population that are resistant 
to chemotherapy and have enriched sphere forming 
activity [29]. To our knowledge, our study is the first to 
explore the relationship between C/EBPβ and ALDH 
in Ewing sarcoma. Our data suggest that high levels of 
C/EBPβ lead to increased transformation, increased 
ALDH1A1 expression and activity, and chemotherapy 
resistance. Targeting ALDH-high cells in Ewing sarcoma 
may improve treatments in the future.
RESULTS
C/EBPβ is highly expressed in Ewing sarcoma
To determine if C/EBPβ is expressed in Ewing 
sarcoma cells, we interrogated the Broad Institute’s Cancer 
Cell Line Encyclopedia (CCLE) [30] for expression of 
CEBPB. Out of the 37 different cancer types evaluated, 
Ewing sarcoma had the highest CEBPB expression on 
average (Figure 1A). Additionally, we evaluated the 
microarray dataset GSE1825 [31] from the GEO database 
for CEBPB expression in Ewing sarcoma patient samples 
compared to neuroblastoma patient samples and found 
significantly higher CEBPB expression in the Ewing 
sarcoma samples (P = 0.016) (Figure 1B). 
Our initial study of CNAs in Ewing sarcoma 
identified a focal region of amplification in a subset of 
Ewing sarcoma tumors that contained five genes: RNF114, 
SNAI1, UBE2V1, TMEM189, and CEBPB. We used the 
same dataset (GSE1825) to evaluate expression of all 
five genes within the focal region of high copy gain in 
the Ewing sarcoma samples compared to neuroblastoma 
samples. Although SNAI1 is a well-known gene involved 
in epithelial to mesenchymal transition in many cancers, it 
does not appear to be highly expressed in Ewing sarcoma 
tumors (Figure 1B). We further evaluated expression of 
these five genes in Ewing sarcoma tumor samples by 
microarray. Of the five genes, CEBPB mRNA expression 
levels in patient tumors corresponds most consistently 
with the number of copies of this region (Figure 1C), 
supporting the previously reported levels of protein 
expression by IHC [9]. 
Finally, a panel of Ewing sarcoma cell lines was 
screened for expression of each of the three protein 
C/EBPβ isoforms by Western blot. A breast cancer cell 
line (MCF7) and an anaplastic large cell lymphoma cell 
line (SuDHL1), previously reported to express C/EBPβ 
[23, 32], were included as positive controls (Figure 1D). 
Each of the 7 Ewing sarcoma cell lines (A673, CHLA9, 
CHLA10, CHLA258, TC71, TC252, and SKNMC) 
tested expressed all three protein isoforms of C/EBPβ 
in varying levels. Based on these results combined 
with the documented role of C/EBPβ in cancer and 
bone development, we decided to focus our efforts on 
understanding the functional role of C/EBPβ in Ewing 
sarcoma.
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Figure 1: CEBPB expression in Ewing sarcoma. (A) CEBPB expression was interrogated in cancer cell lines from the Cancer Cell 
Line Encyclopedia (Broad Institute). Ewing sarcoma cell lines had the highest CEBPB mRNA expression on average compared to any other 
cancer type. (B) Data from the GEO dataset GSE1825 was analyzed to determine relative mRNA expression of the genes within the region 
of high copy number gain on chromosome 20q in Ewing sarcoma patient samples compared to neuroblastoma patient samples (CEBPB: 
P = 0.016). (C) Relative mRNA expression of 4 genes within the region of gain on chromosome 20q with normal or increased copy number 
in Ewing sarcoma patient samples. (D) Expression of the C/EBPβ protein isoforms in Ewing sarcoma cell lines by Western blot. MCF7 
(breast cancer) and SuDHL1 (anaplastic large cell lymphoma) were included as positive controls, and GAPDH serves as a loading control.
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Expression of C/EBPβ in Ewing sarcoma cells is 
controlled by EWS-FLI1
To determine whether the causative Ewing sarcoma 
translocation, EWS-FLI1, influences expression of 
C/EBPβ in Ewing sarcoma, we transduced a Ewing 
sarcoma cell line (A673) with a lentivirus expressing a 
shRNA targeting the 3’ untranslated region (3′ UTR) of 
FLI1. This shRNA was previously validated and shown 
to specifically target EWS-FLI1 in Ewing sarcoma cells 
[8]. Treatment with this shRNA led to a significant 
decrease in EWS-FLI1 protein and mRNA expression, 
as well as knockdown of protein and mRNA expression 
of all three C/EBPβ isoforms and NR0B1, a known 
target of EWS-FLI1 [7] (Figure 2A, 2B). To verify that 
this decrease in C/EBPβ expression was not due to an 
off-target effect by the shRNA, we transduced cells 
expressing FLI shRNA with a shRNA-resistant EWS-
FLI1 expression construct to rescue expression of the 
fusion gene. Cells successfully transduced with both 
viruses were selected for 72 hours in puromycin (2 µg/
ml) and G418 (500 µg/ml). Upon re-expression of EWS-
FLI1, protein and mRNA expression of the C/EBPβ 
isoforms increased, indicating that C/EBPβ, like NR0B1, 
is regulated by EWS-FLI1 (Figure 2A, 2B). This is 
supported by publicly available EWS-FLI1 knockdown 
data in additional Ewing sarcoma cell lines [33, 34] 
(Supplementary Figure 1A, 1B). However, due to the lack 
of GGAA microsatellites in the CEBPB promoter region 
and EWS-FLI1 chIP-seq data generated by others [5, 6], 
we conclude that regulation of CEBPB by EWS-FLI1 
is indirect and not mediated by direct binding of the fusion 
to the gene promoter. 
C/EBPβ does not affect cell proliferation and 
viability in Ewing sarcoma in 2D culture
To evaluate the functional consequences of C/EBPβ 
isoform expression in Ewing sarcoma, each of the 
three C/EBPβ isoforms were expressed individually in 
Ewing sarcoma cell lines by retroviral transduction. To 
determine which isoforms, if any, affect the rate of cell 
proliferation in standard culture conditions (2D culture), 
we overexpressed each of the C/EBPβ isoforms in Ewing 
sarcoma cell lines and calculated cell doubling time by the 
3T5 assay [35]. There was no difference in cell doubling 
time with overexpression of any of the three isoforms 
compared to the empty vector control (Figure 3A). 
Similarly, when CEBPB was knocked down with shRNA 
that targets the 3′UTR of CEBPB (7440; Supplementary 
Figure 2A) there was no significant decrease in cell 
proliferation, and there was no significant increase in cell 
proliferation with rescue of any of the C/EBPβ isoforms 
(Figure 3B, 3C). Additionally, we measured no difference 
in cell viability over time with CEBPB knockdown and 
rescue, or after 72 hours following overexpression of 
the different C/EBPβ isoforms (Figure 3C, 3D). These 
results suggest that C/EBPβ expression does not affect 
cell proliferation and viability in Ewing sarcoma cells in 
2D culture.
C/EBPβ overexpression promotes 
transformation in Ewing sarcoma cells
To determine the effect of C/EBPβ expression on 
cellular transformation, Ewing sarcoma cell lines were 
transduced to express each of the three C/EBPβ isoforms 
individually. Following antibiotic selection, cells were 
grown in attachment-independent conditions (soft agar) for 
2–4 weeks, and cell viability was measured and colonies 
were counted. We observed an increase in cell viability, 
colony number, and colony size with overexpression of 
C/EBPβ-1 and C/EBPβ-2 (Figure 4). Conversely, there 
was a decrease in colony formation with knockdown 
of CEBPB expression compared to treatment with a 
non-targeting shRNA control (GFP) (Figure 4B–4D; 
Supplementary Figure 2A). To rule out the possibility 
that the decrease in colony formation is due to shRNA 
off-target effects, C/EBPβ expression was rescued 
by transducing C/EBPβ knockdown or control (GFP) 
knockdown cells with retroviruses encoding each 
C/EBPβ isoform. The colony-formation phenotype was 
rescued with overexpression of C/EBPβ-1 and C/EBPβ-2 
following knockdown (Figure 4B–4D), suggesting 
that C/EBPβ-1 and C/EBPβ-2 expression increases 
transformation of Ewing sarcoma cells. 
ALDH1A1 is a target of C/EBPβ
We explored potential downstream targets of 
C/EBPβ by microarray in four Ewing sarcoma cell lines 
(A673, CHLA9, CHLA10, TC252) harboring altered 
C/EBPβ-1 expression: C/EBPβ lentiviral knockdown; 
C/EBPβ-1 retroviral overexpression; C/EBPβ-1 
rescue by lentiviral knockdown followed by retroviral 
overexpression; empty vector and non-targeting shRNA 
control treatment; and untreated cells (Supplementary 
Figure 3A, 3C). RNA from these cells was run on the 
Human Transcriptome Array 2.0 (Affymetrix). There 
were 43 genes that had greater than 1.25 fold change and 
P-value < 0.05 (permutation test) between C/EBPβ-1 
knockdown and C/EBPβ-1 overexpression. HSD11B1, 
PI3, SQRDL, ALDH1A1, and HCAR2 were the top 
5 most differentially expressed genes when comparing 
normalized C/EBPβ-1 depleted cells with normalized 
C/EBPβ-1 overexpressing cells in all four cell lines 
(Figure 5A, Supplementary Table 1). 
Because of its role as a cancer stem cell 
marker and its involvement in transformation and 
chemoresistance [26–29], we directed our focus to 
understanding ALDH1A1 in Ewing sarcoma and its 
relationship to C/EBPβ. Additionally, previous reports 
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have demonstrated the presence of a CCAAT box in the 
promoter region of ALDH1A1 where C/EBPβ interacts 
to promote transcription [25, 36]. To validate the array 
data, ALDH1A1 protein expression was measured by 
Western blot in Ewing sarcoma cell lines with C/EBPβ-1 
depletion, rescue, and overexpression. We observed an 
increase in ALDH1A1 protein expression with C/EBPβ-1 
overexpression and a decrease in ALDH1A1 protein 
expression with C/EBPβ-1 knockdown (Figure 5B). We 
further measured CEBPB and ALDH1A1 transcript levels 
in these cells by qRT-PCR and observed a similar trend: 
ALDH1A1 transcript levels positively correspond to 
CEBPB levels (Figure 5C; Supplementary Figure 3B, 3C). 
This suggests that C/EBPβ functions as a transcriptional 
regulator of ALDH1A1 in Ewing sarcoma. 
C/EBPβ overexpressing cells have high ALDH 
activity
A subpopulation of Ewing sarcoma cells express high 
levels of ALDH, and this ALDH-high population has been 
shown to have stem cell like properties, increased colony 
formation, and increased chemoresistance compared to 
ALDH-low Ewing sarcoma cells [29]. Based on this 
previous report, we explored the possibility that increased 
expression of C/EBPβ leads to increased activity of ALDH. 
Ewing sarcoma cells overexpressing the C/EBPβ isoforms 
were subject to the Aldefluor assay to measure ALDH 
activity. Cells were treated with diethylaminobenzaldehyde 
(DEAB), an ALDH inhibitor, as a negative control. ALDH 
activity was measured through the Aldefluor assay by flow 
cytometry, where FITC-positive cells represent high ALDH 
activity. Cells overexpressing C/EBPβ-1 had a greater 
population of ALDH-high cells, suggesting these cells 
have greater ALDH activity compared to controls and cells 
overexpressing C/EBPβ-2 or -3 (P < 0.005) (Figure 6A, 6B). 
When C/EBPβ-1 was knocked down in Ewing sarcoma 
cells, there was a decrease in ALDH activity; and ALDH 
activity increased with rescued expression of C/EBPβ-1 
(Figure 6C; Supplementary Figure 4). This indicates that C/
EBPβ-1 overexpressing cells not only have high ALDH1A1 
levels, but high ALDH activity.
C/EBPβ-1 overexpressing cells are resistant to 
chemotherapies
To evaluate whether C/EBPβ expression affects 
the cellular response to chemotherapies, Ewing 
sarcoma cells transduced to express each isoform of 
C/EBPβ were treated with doxorubicin, part of the 
regular chemotherapeutic regimen for Ewing sarcoma 
patients. Cells grown in normal, attachment-dependent 
conditions, overexpressing either C/EBPβ-1 or C/EBPβ-2, 
had significantly increased viability after 48 hours of 
doxorubicin treatment compared to control cells (empty 
vector) and C/EBPβ-3 overexpressing cells (P < 0.05) 
(Figure 7A; Supplementary Figure 5A). Additionally, 
there was a decrease in cell viability after 48 hours of 
Figure 2: C/EBPβ expression in Ewing sarcoma cells is regulated by EWS-FLI1. (A) EWS-FLI1 was knocked down with 
FLI1 shRNA and rescued in A673 cells. Luc is a non-targeting shRNA control and MSCV is an empty vector control. Expression of 
EWS-FLI1 and C/EBPβ protein isoforms was analyzed by Western blot, with GAPDH as a loading control. FLI1 and C/EBPβ bands 
were quantified by densitometry. (B) EWS-FLI1 was knocked down and rescued in A673 cells. Relative EWS-FLI1 and CEBPB transcript 
levels were measured by qRT-PCR. Multiple t tests were applied to determine statistical significance. (P-value for experimental vs control: 
*P < 0.05, **P < 0.005, ***P < 0.0001; P-value for experimental vs knockdown: +P < 0.05, ++P < 0.005, +++P < 0.0001.).
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Figure 3: C/EBPβ isoform expression does not affect cell proliferation or viability in 2D culture. (A) C/EBPβ isoforms were 
overexpressed in CHLA9 cells. Population doubling time was calculated by the 3T5 assay. (B) CEBPB was knocked down, then each isoform 
was rescued in CHLA10 cells. Population doubling time was calculated by the 3T5 assay. (C) CEBPB was knocked down then C/EBPβ-1 
was rescued in A673 cells. Cell viability was measured over time with Cell Titer Glo (Promega) with raw luminescence values representing 
cell viability. (D) CEBPB isoforms were overexpressed in TC252 cells. Cell viability was measured 72 hours after cells were plated. Multiple 
t tests demonstrate no statistical difference between treatments and control. Western blots in all panels show C/EBPβ isoform expression, 
with GAPDH included as a protein loading control. E = empty vector (control); C1 = C/EBPβ-1; C2 = C/EBPβ-2; C3 = C/EBPβ-3.
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Figure 4: C/EBPβ-1 promotes attachment-independent cellular transformation. (A) C/EBPβ isoforms were overexpressed 
in TC252 cells and grown in soft agar. Colonies were imaged and cell viability was measured after 14 days. (B) C/EBPβ was depleted, 
then each isoform was rescued in CHLA10 cells. Cells were grown in soft agar and colonies were imaged and cell viability measured after 
16 days. (C) C/EBPβ was depleted and C/EBPβ-1 was rescued or overexpressed in A673 cells. Cells were grown in soft agar and colonies 
were imaged and cell viability was measured after 14 days. (D) C/EBPβ was depleted and C/EBPβ-1 was rescued or overexpressed in 
CHLA9 cells. Cells were grown in soft agar and colonies were imaged and counted after 27 days. Protein expression of each of the three 
overexpressed, knocked down, or rescued isoforms in each panel is shown. GAPDH is included as a loading control. Multiple t tests were 
performed to determine statistical difference between treatments and control in each experiment. (P-value for experimental vs control: 
*P < 0.05, **P < 0.005, ***P < 0.0001; P-value for experimental vs knockdown: +P < 0.05, ++P < 0.005, +++P < 0.0001). E = empty vector 
(control); C1 = C/EBPβ-1; C2 = C/EBPβ-2; C3 = C/EBPβ-3.
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Figure 5: ALDH1A1 is a target of C/EBPβ-1. (A) Heat map of differentially expressed genes between C/EBPβ-1 knockdown and C/EBPβ-1 
overexpression normalized to control in four Ewing sarcoma cell lines. Gene list was ranked by average fold-change between C/EBPβ-1 
knockdown and overexpressed samples normalized to control sample in each cell line. Top 43 genes (fold change > 1.25; permutation test 
P < 0.05) that positively correlated to C/EBPβ-1 expression are shown on the list. P-values by t-test for all genes included on the heat map 
are listed. (B) ALDH1A1 protein expression was analyzed by Western blot in A673 and CHLA9 cells with C/EBPβ knockdown, rescue, 
and overexpression. ALDH1A1 bands were quantified by densitometry. (C) Relative expression of CEBPB and ALDH1A1 mRNA in the 
same cells as in B. Expression was normalized to endogenous GAPDH. Multiple t tests were performed to determine statistical significance 
among treatments. (P-value for experimental vs control: *P < 0.05, **P < 0.005, ***P < 0.0001; P-value for experimental vs knockdown: 
+P < 0.05, ++P < 0.005, +++P < 0.0001). E = empty vector (control); C1 = C/EBPβ-1; C2= C/EBPβ-2; C3= C/EBPβ-3.
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doxorubicin treatment when C/EBPβ was depleted by 
shRNA; and viability returned to control levels with 
rescued expression of C/EBPβ-1 (Figure 7B). These 
results suggest that Ewing sarcoma cells with increased 
expression of C/EBPβ-1 or C/EBPβ-2 are more 
chemoresistant than cells without.
DISCUSSION
To explore the function of C/EBPβ isoforms 
in Ewing sarcoma, we overexpressed each of the 
three C/EBPβ isoforms in Ewing sarcoma cell lines. 
Overexpression of C/EBPβ-1 and C/EBPβ-2 resulted 
in significant increases in cellular transformation as 
measured by colony formation in soft agar. Interestingly, 
in breast cancer, C/EBPβ-2 is the isoform capable of 
transforming normal mammary epithelial cells [22]. In 
Ewing sarcoma cells, both C/EBPβ-1 and C/EBPβ-2 
increase transformation, yet the increase in colony 
formation is consistently greater with overexpression of 
C/EBPβ-1 compared to C/EBPβ-2. C/EBPβ-1 protein was 
more highly expressed compared to C/EBPβ-2 in each cell 
line tested, which may account for the difference in colony 
formation observed between the two isoforms. 
Cellular context appears to play an important role in 
the Ewing sarcoma cell response to increased expression 
of the C/EBPβ isoforms, particularly C/EBPβ-3. 
In some cell lines, C/EBPβ-3 inhibits colony formation 
(Figure 4A, 4B), while C/EBPβ-3 overexpression in 
other cell lines increases colony formation (data not 
shown). Likewise, C/EBPβ-3 overexpression in TC252 
did not confer resistance to doxorubicin, while C/EBPβ-3 
overexpression in CHLA10 did (Figure 7A, 
Supplementary Figure 5A). This difference may result 
from variation in the level of C/EBPβ-3 expression in 
each cell line. Additionally, these differences may be due 
to the ratio of expression of each isoform, as C/EBPβ-3 
is capable of antagonizing the larger isoforms in certain 
contexts [15]. Previous studies have shown the importance 
of C/EBPβ isoform ratios in bone development and cell 
Figure 6: ALDH activity is influenced by C/EBPβ expression. (A) Representative FACS analysis of TC252 cells subject to the 
Aldefluor Assay. Percentage of viable cells that are gated as ALDH-high (FITC positivity) is shown. (B) Percentage of live TC252 cells 
from A that are gated as ALDH-high with overexpression of each C/EBPβ isoform. (C) C/EBPβ was depleted, rescued, and overexpressed 
in A673, CHLA9, and CHLA10 cells, and cells were subject to the Aldefluor Assay. Percentage of live cells that are gated as ALDH-high 
in each condition is shown. Multiple t tests were used to determine statistical significance. (P-value for experimental vs control: *P < 0.05, 
**P < 0.005, ***P < 0.0001; P-value for experimental vs knockdown: +P < 0.05, ++P < 0.005, +++P < 0.0001). E = empty vector (control); 
C1 = C/EBPβ-1; C2 = C/EBPβ-2; C3 = C/EBPβ-3.
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cycle progression in the liver [16, 37]. However, since 
both cell lines express a high level of this isoform, we 
favor the alternative possibility that differences in cellular 
context lead to the observed variation in colony formation 
and drug resistance. These two cell lines may also express 
varying levels of downstream targets of C/EBPβ, which 
would affect their response to C/EBPβ expression in a cell 
line dependent manner.
The retroviral expression system used in this study 
did not allow us to control the level of C/EBPβ expression. 
The level of expression in these in vitro experiments may 
not accurately reflect the amount of increased protein 
expression in patient cells. However, even if the amount 
of C/EBPβ expressed in our transduced cell lines was 
greater than that of patient tumors, knockdown of C/EBPβ 
expression significantly decreased colony formation and 
increased chemosensitivity, further supporting a critical role 
for this gene in Ewing sarcoma transformation and growth.
In an effort to better understand how C/EBPβ 
upregulation increases transformation potential in Ewing 
sarcoma, we sought to identify downstream targets of 
C/EBPβ. By microarray analysis, we identified aldehyde 
dehydrogenase 1A1 (ALDH1A1) as a target of C/EBPβ. 
In breast cancer cell lines, C/EBPβ-2 has been shown 
to regulate ALDH1A1 expression [25]. ALDH1A1 is an 
aldehyde dehydrogenase involved in alcohol metabolism 
and oxidation of cellular aldehydes. High expression of 
ALDH1A1 is found in many cancers and is frequently 
considered a marker of cancer stem cells [28, 29, 38]. 
C/EBPβ-1 overexpressing cells had high transcript and 
protein levels of ALDH1A1, as well as high ALDH 
activity. Furthermore, overexpression of C/EBPβ-1 and 
C/EBPβ-2 render Ewing sarcoma cells more resistant 
to doxorubicin. This resistance may be mediated in 
part by upregulation of ALDH, as previous studies 
have shown ALDH-high cells to be more resistant to 
chemotherapies compared to ALDH-low cells, though the 
mechanism is not well-understood and warrants further 
investigation [29]. ALDH1A1 may serve as a biomarker 
for treatment resistance in Ewing sarcoma patients. 
Taken together, these results support the oncogenic 
role of C/EBPβ-1 in Ewing sarcoma. The increase in 
cellular transformation and growth with C/EBPβ-1 
overexpression in cell lines may explain the poor outcome 
of patients previously reported to have CEBPB copy 
number gain. As a transcriptional target of EWS-FLI1, the 
causative translocation of the majority of Ewing tumors, 
CEBPB is likely up-regulated in many cases of Ewing 
sarcoma. Further, as a transcription factor itself, C/EBPβ 
regulates the expression of downstream targets, such as 
ALDH1A1, a potential cancer stem cell marker in Ewing 
sarcoma and a superior therapeutic target. Understanding 
the molecular contributions of C/EBPβ to ALDH1A1 
and other downstream targets in Ewing sarcoma warrants 
further investigation.
MATERIALS AND METHODS
Cell culture
A673 (American Type Culture Collection), CHLA9 
and CHLA10 (Children’s Oncology Group Cell Culture 
and Xenograft Repository), and TC252 were used in this 
study. A673 cells were cultured in DMEM supplemented 
with 10% fetal bovine serum, 1% glutamax, and 1% 
sodium pyruvate. TC252 cells were cultured in RPMI 
supplemented with 10% fetal bovine serum and 1% 
glutamax. CHLA9 and CHLA10 cells were cultured 
in IMDM supplemented with 20% fetal bovine serum, 
2% glutamax, and 1% insulin-transferrin-selenium. All 
Figure 7: C/EBPβ  overexpression leads to chemoresistance in Ewing sarcoma cells. (A) Each of the C/EBPβ  isoforms were 
overexpressed in TC252 cells. Cells were treated with the indicated doses of doxorubicin for 48 hours, then viability was measured. (B) 
C/EBPβ was depleted, then C/EBPβ-1 was rescued in TC252 cells. Cells were treated with doxorubicin for 48 hours, then cell viability was 
measured. Multiple t tests were performed to determine statistical difference between treatments and controls. (P-value for experimental vs 
control: *P < 0.05, **P < 0.005, ***P < 0.0001; P-value for experimental vs knockdown: +P < 0.05, ++P < 0.005, +++P < 0.0001). E = empty 
vector (control); C1 = C/EBPβ-1; C2 = C/EBPβ-2; C3 = C/EBPβ-3.
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experiments were performed within 6 months of cell line 
resuscitation, and cell line authentication was performed 
by providers by STR profiling.
Cloning
CEBPB was cloned from an Origene Human 
cDNA clone (SC319561, Origene; accession number 
NM_005194.2). The following primers were used to 
amplify CEBPB: forward primer for CEBPB-1 - 5′- 
GTC CGG AAT TCG CCG CCG CCATGC AAC 
GCCTGGTGG CCT G -3′, forward primer for CEBPB-2 
- 5′- GTC CGG AAT TCG CCG CCG CCATGG 
AAGTGG CCA ACT TCT ACT ACG AGG CG -3′, and 
forward primer for CEBPB-3 - 5′- GTC CGG AAT TCG 
CCG CCG CCATGG CGG CGG GCT TCC CGT ACG 
-3′. The same reverse primer was used to clone all three 
isoforms: 5′- GAATTA AGATCT CTA GCA GTG GCC 
GGA GGA GGC GA -3′. These primers add restriction 
sites for cloning and a Kozak consensus sequence for 
translation. Platinum Pfx DNA Polymerase kit (Life 
Technologies) with enhancer was used to amplify each 
isoform. Product sizes were verified by running the 
samples on 1.5% agarose gels and visualizing bands with 
UV light. Bands of the appropriate size were cut from 
the gels and purified using the QIAquick Gel Extraction 
Kit (Qiagen). Next, the PCR products and empty vector 
MSCVneo (Clontech) were digested with EcoRI and 
BglII. Digested vector and inserts were gel purified as 
above, followed by ligation with T4 DNA Ligase (Life 
Technologies). Stbl3 (Life Technologies) chemically 
competent bacteria were transformed by heat shock. Four 
colonies from each transformation were screened after 
miniprep (Qiagen Miniprep Kit) by digesting with EcoRI 
and BglII. Plasmids with inserts of the appropriate size 
were confirmed by Sanger sequencing (University of Utah 
DNA Sequencing Core).
Viral packaging
Five CEBPB MISSION shRNA Plasmid DNA 
(Sigma) clones were used in knockdown experiments 
(TRCN0000007440, TRCN0000007441, TRCN0000007442, 
TRCN0000007443, TRCN0000007444). shRNA 
lentivirus was packaged in HEK293 cells using Sigma 
Mission Lentiviral Packaging mix. For overexpression, 
MSCV constructs containing CEBPB were packaged into 
retroviruses by co-transfection with packaging plasmids in 
293-EBNA (Life Technologies) cells.
Viral transduction of cell lines
300,000-500,000 Ewing sarcoma cells were plated 
in 6-well culture plates. Following adherence of cells 
(6–24 hours), lentivirus or retrovirus was added along 
with 10 µg/ml Polybrene (Millipore). After 24 hours in 
culture, media containing virus was removed and media 
containing antibiotic was added. Cells were cultured for 
at least 72 hours in 2 µg/ml puromycin or 120 hours in 
500 µg/ml G418 to select for successfully transduced cells. 
Experiments were carried out in the presence of antibiotic.
Western Blot
Cells were lysed in Cell Lysis Buffer (Cell Signaling 
Technology) supplemented with Protease/Phosphatase 
Inhibitor Cocktail (Cell Signaling Technology). 30–50 µg 
of total protein lysate was run on Bolt 10% Bis-Tris Plus 
or NuPAGE 7% Tris-Acetate gels (Life Technologies) 
and transferred to PVDF membranes (Life Technologies). 
Membranes were blocked in StartingBlock T20 (TBS) 
blocking buffer (Thermo Scientific), and proteins were 
detected with the following antibodies: rabbit monoclonal 
Anti-C/EBP-β (Clone E299, Millipore), rabbit polyclonal 
Anti-FLI1 (ab15289, Abcam), rabbit polyclonal Anti-
DAX1 (also known as NR0B1, sc-841, Santa Cruz 
Biotechnology), rabbit monoclonal Anti-ALDH1A1 
(EP1933Y, Abcam), or mouse monoclonal Anti-
GAPDH (Clone GAPDH-71.1, Sigma Aldrich) followed 
by HRP-anti-rabbit or HRP-anti-mouse secondary 
(GE Healthcare Life Sciences). Substrates used for 
detection were SuperSignal West Dura Chemiluminescent 
Substrate (Thermo Scientific) and Western Lightning 
Ultra (PerkinElmer). Signal was detected with a Bio-
Rad ChemiDoc Gel Imager or developed on Amersham 
Hyperfilm ECL (GE Healthcare Life Sciences) or HyBlot 
CL Autoradiography Film (Denville Scientific). Bands 
were quantified using ImageJ.
qRT-PCR
RNA was analyzed by qPCR following the 
EXPRESS qPCR SuperMix Universal protocol 
(Invitrogen) on a StepOne Plus qPCR machine (Applied 
Biosystems). The following primer/probes were used: 
EWS-FLI1 Hs03024807_ft, CEBPB Hs00270923_s1, 
GAPDH Hu GAPDH 4310884E-1003044, and ALDH1A1 
Hs00946916_m1 (all from Applied Biosystems). Samples 
were run in triplicate and normalized to endogenous 
GAPDH expression.
3T5 assay
3T5 Assay was performed as previously 
reported [35]. Briefly, 500,000 cells were plated in 10-cm 
dishes and grown under normal conditions for 3 days. 
Cells were counted, and 500,000 cells plated in new 10-cm 
dish. Process repeated every 3 days for 15 days.
Colony formation and cell viability assay
Following viral transduction and antibiotic selection, 
cells were seeded at 5000 cells/well in triplicate in black 
clear-bottom 96-well plates. Anchorage-dependent cell 
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viability was measured with 1× Cell Titer Glo (Promega) 
prior to culture to confirm equal seeding density and after 
the indicated amount of time in culture. For the soft agar 
colony assay, 50 µl/well of 0.8% Lonza SeaPlaque GTG 
agarose in appropriate media for cell type plus selective 
antibiotic was plated in replicates of 6 in black clear-
bottom 96-well plates. After the bottom layer solidified, 
cells were seeded at 500–1500 cells/well in 0.4% 
Lonza SeaPlaque GTG agarose in appropriate media 
(supplemented with antibiotic) on top of the bottom layer. 
100 µl of media containing antibiotic was added on top 
of the cell layer following solidification. Colonies were 
imaged at 4×-10× magnification and cell viability was 
measured with Cell Titer Glo, 14–28 days after seeding. 
Soft agar assays were also conducted in 12-well plates. For 
these, 600 µl/well of 0.8% Lonza SeaPlaque GTG agarose 
in media appropriate for cell type was added to wells of 
12-well plate and allowed to solidify at room temperature. 
Cells were then seeded at 250–1000 cells/well in 0.4% 
Lonza SeaPlaque GTG agarose in appropriate media on 
top of bottom layer and allowed to solidify. 500 µl of 
media containing selective antibiotic was added on top of 
the cell layer. Colonies were imaged and counted using 
ImageJ 2–4 weeks after seeding.
RNA extraction
FFPE tumor ribbons from patients with Ewing 
sarcoma were deparaffinized with Hemo-De, tissue was 
washed twice in 100% ethanol, and allowed to air dry for 
45 minutes. Tissue was digested and RNA was isolated 
following the Recoverall Total Nucleic Acid Isolation 
protocol (Ambion Life Technologies). RNA was isolated 
from cell lines using QIAGEN’s RNeasy Mini protocol 
with QIAshredder (QIAGEN). RNA was treated with 
DNase using the TURBO DNA-free Kit (Ambion Life 
Technologies) and quantified using Quant-iT Ribogreen 
RNA Reagent and Kit (Invitrogen).
Drug treatment
Ewing sarcoma cells transduced with CEBPB 
isoforms were seeded at 1000 cells/well in black clear-
bottom 96-well tissue culture plates. 24 hours following 
seeding, doxorubicin was added at the indicated 
concentrations. DMSO was used as a no-treatment control 
(doxorubicin stock was dissolved in DMSO). Cell viability 
was measured with Cell Titer Glo (Promega) 48 hours 
following drug treatment. 
Gene expression analysis
RNA from each condition in each cell line (A673, 
CHLA9, CHLA10, TC252) was collected and processed 
using the SensationPlus™ FFPE Amplification and WT 
Labeling Kit, optimized for FFPE samples, according to 
the manufacturer’s protocol (Affymetrix, Santa Clara, CA). 
Briefly, 50 ng of total RNA was used for first strand cDNA 
synthesis using a random/dT primer mix. Addition of a 
poly A tail and T7 promoter region allowed for in vitro 
transcription of senseRNA. The senseRNA was then 
reverse transcribed to produce double stranded cDNA, 
which was fragmented, labeled and hybridized to the 
human transcriptome array (HTA) 2.0 (Affymetrix, Santa 
Clara, CA). Raw Affymetrix CEL files were processed by 
Affymetrix Expression Console (1.4.1) at the gene level and 
exon level. Background correction and normalization were 
done by the RMA-Sketch algorithm. The processed data 
were exported in a matrix that contains log2 intensity values 
for each probe set. For each gene, the levels in C/EBPβ 
overexpression or knockdown treatments were normalized 
to the level of control in each cell line. Normalized 
data were used to generate a heat map of differentially 
expressed genes by GENE-E (Broad). Samples were 
grouped by the condition of C/EBPβ (normalized to 
control): overexpression or knockdown. The final gene 
list was ranked based on fold-changes and includes the 
genes with fold-change of overexpression to knockdown > 
1.25 and P-value < 0.05 (permutation test). No multiple 
comparisons tests were performed due to our small sample 
size. Individual gene P-values of the most differentially 
expressed genes were calculated using the t-test.
Aldefluor assay
The Aldefluor Assay (Stem Cell Technologies) 
was performed on Ewing sarcoma cells according to the 
manufacturer’s protocol. Cells were analyzed by flow 
cytometry using a BD FACSCanto Analyzer and FlowJo 
software. Viable cells were gated based on propidium-
iodide exclusion. ALDH-high cells were quantified by 
gating the top 2% of FITC+ empty vector control cells.
Statistical analysis
Multiple t tests were applied to analyze statistical 
differences among treatments, unless otherwise indicated. 
Asterisks in the figures indicate significance to the 
empty vector (negative) control (*P < 0.05, **P < 0.005, 
***P < 0.0001) and plus signs in the figures indicate 
significance to the knockdown (+P < 0.05, ++P < 0.005, 
+++P < 0.0001).
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